## Dysgerminoma Management: Stage IA Disease **Key Point:** For stage IA dysgerminoma (confined to one ovary, completely resected, normal tumor markers), **observation alone with serial tumor markers and imaging** is the current recommended first-line approach after fertility-sparing surgery, reserving BEP chemotherapy for relapse. ### Current Evidence-Based Approach **High-Yield:** Stage IA dysgerminoma has an excellent prognosis after complete surgical resection (unilateral salpingo-oophorectomy). Contemporary guidelines (NCCN, ESGO) recommend **surveillance/observation** as the preferred strategy for stage IA disease because: 1. **Cure rates with surgery alone are ~75–80%**, and virtually all relapses are salvageable with BEP chemotherapy. 2. **Overall survival approaches 95–100%** even with a watch-and-wait strategy, since chemotherapy at relapse is highly effective. 3. Avoiding upfront chemotherapy **preserves fertility** and spares young patients from unnecessary toxicity (bleomycin pulmonary toxicity, cisplatin nephrotoxicity/ototoxicity, etoposide-related secondary leukemia risk). **Clinical Pearl:** Dysgerminoma is the female equivalent of testicular seminoma. Just as stage I seminoma is managed with surveillance after orchiectomy (not immediate adjuvant chemotherapy), stage IA dysgerminoma is managed with observation after USO. The high chemosensitivity at relapse makes upfront treatment unnecessary. ### Treatment Algorithm for Dysgerminoma | Stage | Primary Treatment | Notes | |-------|------------------|-------| | **IA (completely resected)** | **Observation** | BEP reserved for relapse; OS ~95–100% | | IC–II | BEP × 3 cycles | Higher recurrence risk justifies adjuvant Rx | | III–IV | BEP × 3–4 cycles | Standard for advanced disease | ### Why Not Upfront BEP for Stage IA? **High-Yield:** The original teaching that "all dysgerminomas need adjuvant chemotherapy" is outdated. Modern oncology (per Williams Gynecology, NCCN 2023, and Berek & Hacker's Gynecologic Oncology) endorses **observation** for stage IA because: - Recurrence risk (~20–25%) is acceptable given near-100% salvage rates with BEP at relapse. - Treating all stage IA patients exposes ~75–80% of women to chemotherapy they will never need. - Long-term sequelae (secondary malignancy, infertility, organ toxicity) are avoided. ### Why Not Radiation? Radiation therapy (option C) is avoided in young women due to long-term gonadal toxicity, bowel complications, and secondary malignancy risk. It has been replaced entirely by chemotherapy when systemic treatment is needed. **Mnemonic:** **Stage IA Dysgerminoma = Surgery + Surveillance** (Save BEP for relapse — it works 100% of the time when needed!) ### Fertility Preservation **Clinical Pearl:** Unilateral salpingo-oophorectomy (USO) with preservation of the contralateral ovary and uterus is the surgical standard. Observation after USO maximizes fertility preservation by avoiding gonadotoxic chemotherapy in the majority of patients who will not relapse. *Reference: Berek & Hacker's Gynecologic Oncology, 6th ed.; NCCN Guidelines — Ovarian Cancer (Germ Cell Tumors), 2023; Williams Gynecology, 4th ed.*
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.